17^th European Biosimilars Congress

Biography

Biography: Mohamed Abdel Raof Elsisi

Abstract

A biosimilar medicine is a biologic medication that is extremely similar to a reference medicine that the FDA has already approved. Kanjinti as an immunotherapy is biosimilar to Herceptin (reference medicine) with active ingredient trastuzumab. Clinics have had difficulties since switching from reference medicine Herceptin to a biosimilar for anti-HER2 therapy. There are extremely few or no real-world data on trastuzumab biosimilars available. To verify safety and efficacy. Therefore we conduct case report on Kanjinti. Female patient 45 years, Peri-Menopausal, married and has five children, negative family history of malignancy, At March 2023 patient diagnosed as left breast cancer. Patient did left MRM, revealed intra-ductal carcinoma grade III, With DCIS+ LVI, Pt2N2A, Er Week +Ve, Er -Ve, Her2 +Ve score 3, the initial decision taken is to give taxol with Trastuzumab with Pertuzumab X six cycles then to receive Trastuzumab with Pertuzumab for total doses (17 Doses). Patient received only one dose Taxol and medical report given to them, that patient is not eligible for treatment with Trastuzumab and Pertuzumab. So the decision was to give Adriamycin and cyclophosphamide (AC) Protocol X four cycles, then Taxol with Herceptin X three Cycles, then PORTH, after that continue Herceptin till total doses 17 doses with supportive treatment and hormonal therapy X five years, patient received four cycles AC protocol, then taxol 175 mg/m2 with Kanjinti x three cycles. The first loading dose of Kanjinti was 600mg, then maintenance dose 450mg then patient received PORTH and then continued KANJINTI with hormonal therapy NOLVADEX 20mg daily, received total seven cycles of KANJINTI with no adverse events, with good tolerance and excellent clinical response without any disease progression. That reflects the high efficacy and safety of trastuzumab biosimilar (Kanjinti).